# Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

> **NCT05929222** · PHASE3 · RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 190 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **RADIATION:** Radiotherapy
- **OTHER:** Radiotherapy plus Obinutuzumab

## Key facts

- **NCT ID:** NCT05929222
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-14
- **Primary completion:** 2031-04
- **Final completion:** 2031-04
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05929222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05929222, "Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05929222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*